- Home
- ARQT vs STEW Comparison
ARQT vs STEW Comparison
Compare ARQT & STEW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- STEW
- Stock Information
- Founded
- ARQT 2016
- STEW 1972
- Country
- ARQT United States
- STEW United States
- Employees
- ARQT N/A
- STEW N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- STEW Investment Managers
- Sector
- ARQT Health Care
- STEW Finance
- Exchange
- ARQT Nasdaq
- STEW Nasdaq
- Market Cap
- ARQT 2.1B
- STEW 1.8B
- IPO Year
- ARQT 2020
- STEW N/A
- Fundamental
- Price
- ARQT $17.71
- STEW $18.22
- Analyst Decision
- ARQT Strong Buy
- STEW
- Analyst Count
- ARQT 7
- STEW 0
- Target Price
- ARQT $19.00
- STEW N/A
- AVG Volume (30 Days)
- ARQT 1.6M
- STEW 84.5K
- Earning Date
- ARQT 11-05-2025
- STEW 01-01-0001
- Dividend Yield
- ARQT N/A
- STEW 3.71%
- EPS Growth
- ARQT N/A
- STEW N/A
- EPS
- ARQT N/A
- STEW 1.44
- Revenue
- ARQT $263,464,999.00
- STEW N/A
- Revenue This Year
- ARQT $72.46
- STEW N/A
- Revenue Next Year
- ARQT $31.69
- STEW N/A
- P/E Ratio
- ARQT N/A
- STEW $10.34
- Revenue Growth
- ARQT 99.50
- STEW N/A
- 52 Week Low
- ARQT $8.03
- STEW $11.97
- 52 Week High
- ARQT $18.15
- STEW $14.94
- Technical
- Relative Strength Index (RSI)
- ARQT 63.97
- STEW 51.02
- Support Level
- ARQT $16.62
- STEW $18.12
- Resistance Level
- ARQT $18.15
- STEW $18.43
- Average True Range (ATR)
- ARQT 0.69
- STEW 0.16
- MACD
- ARQT 0.03
- STEW -0.05
- Stochastic Oscillator
- ARQT 85.57
- STEW 17.27
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About STEW SRH Total Return Fund Inc.
SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total returns. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.